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Objectives: To evaluate the effect of deep brain stimulation of the subthalamic nucleus
(STN-DBS) on alexithymia, a deﬁcit in affective regulation, comparing patients with
Parkinson’s disease (PD) submitted to STN-DBS (DBS group) to PD patients not yet treated
with STN-DBS (pre-DBS group) and to healthy participants (C group).
Methods: We recruited 27 consecutive STN-DBS PD patients, 38 consecutive pre-DBS
patients and 27 healthy participants. Patients were assessed for alexithymia (Toronto
Alexithymia Scale), depression, [beck depression inventory (BDI)], and cognitive functions
(reasoning, memory, attentional, and executive tests).
Results:The DBS patients performed worse than the pre-DBS patients in the corsi’s block-
tapping test, in the phonemic ﬂuency task and in the Frontal Assessment Battery. Around
30% of DBS (29.6%) and pre-DBS (31.6%) patients resulted alexithymic, compared with
14.8% in the C group.The results pointed out signiﬁcantly higher alexithymia scores in both
the DBS and pre-DBS groups compared with the C group, while no difference emerged
between the DBS and pre-DBS groups. Pre-DBS group showed a signiﬁcantly higher BDI
score than the C group, while DBS group did not.
Conclusion: Although the results suggest that STN-DBS does not affect alexithymia, both
the DBS and pre-DBS patients reported higher prevalence (about 30%) of alexithymia than
did healthy subjects (14.8%).
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INTRODUCTION
Parkinson’s disease (PD) is a common progressive, disabling neu-
rodegenerative disorder with onset of motor and non-motor
features (Müller, 2012), namely with substantial physical, psy-
chological, and social implication (Worth, 2013).
Deep brain stimulation of the subthalamic nucleus (STN-
DBS) is a clinically established procedure for the treatment of
motor symptoms in patients with advanced PD (Witt et al., 2008;
Gervais-Bernard et al., 2009; Odekerken et al., 2013). Although
several studies have demonstrated its efﬁcacy on motor symptoms,
its impact on cognitive and behavioral/psychological aspects is still
controversial and debated (Parsons et al., 2006; Castelli et al., 2008;
Witt et al., 2008; Gervais-Bernard et al., 2009). Some studies have
concluded that STN-DBS is safe from a cognitive standpoint since
it does not lead to general cognitive deterioration (Castelli et al.,
2006; Parsons et al., 2006), others have evidenced a negative impact
on speciﬁc cognitive domains such as memory, attention, verbal
learning, ﬂuency tasks, and executive functions (Witt et al., 2008;
Castelli et al., 2010).
Neuropsychiatric complications such as aggressive and psy-
chotic episodes, apathy, hypomania/mania, depressive episodes,
and affect dysregulation can occasionally, and often transitively,
occur in the post-operative period (Castelli et al., 2006; Witt
et al., 2008, 2012; Strutt et al., 2012). To date, there is no single
explanation for these neuropsychiatric complications: they could
depend on both the indirect inﬂuence of STN stimulation on
the limbic system, including the inﬂuence of electrode place-
ment (Strutt et al., 2012), and on the post-operative reduction
of dopaminergic therapy.
A general consensus has not yet been reached on mood changes
after DBS of STN: most studies have reported either no change or
an improvement in depression after surgery, while others have
reported a worsening of mood state, including suicidal ideation
and attempted completed suicide (Gervais-Bernard et al., 2009;
Strutt et al., 2012; Weintraub et al., 2013), particularly in patients
with a previous history of psychiatric disorder (Lilleeng and
Dietrichs, 2008).
One study does not support direct association between DBS
surgery and increased risk for suicidal ideation and behav-
iors (Weintraub et al., 2013), while another one highlights that
postoperative depression remained a signiﬁcant factor associ-
ated with attempted and completed suicide (Voon et al., 2008).
Given the lack of consensus, the limited number of studies and
the great psycho-social impact of post-operative neuropsychi-
atric and psychological disturbances, these issues warrant further
investigation.
On this basis, the present study aimed at investigating alex-
ithymia, a deﬁcit in affect regulation that has received little
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attention with regard to PD patients, despite its deﬁnition in a
recent study as “a non-motor symptom of PD” (Assogna et al.,
2012). Alexithymia is a personality dimension characterized by an
impairment in identifying and describing feelings, and an impair-
ment in distinguishing between feelings and bodily sensations due
to emotional arousal, compromised symbolization, and an exter-
nally oriented cognitive style, i.e., a tendency to selectively focus on
everything is outward, factual and concrete and to report events
and actionwithout affective involvement (Bagby et al.,1994). Alex-
ithymia can therefore be deﬁned as an inability to recognize and to
communicate emotions. Since previous studies have shown a high
prevalence of this disturbance in PD patients (Assogna et al., 2012)
and since affect dysregulation symptoms have been shown to have
a relevant impact on PD patients (Costa et al., 2010; Assogna et al.,
2012), especially in the ones treated with DBS surgery (Strutt et al.,
2012), further study on this topic are necessary.
To date, no study has addressed the possible impact of STN-
DBS on alexithymia, even though the few studies assessing
alexithymia in PD patients (not treated with STN-DBS) have
shown a high prevalence – about 20% – of this disturbance (Costa
et al., 2010; Assogna et al., 2012).
The main objective of this study is to investigate the effects
of STN-DBS on alexithymia by means of a case-control study
comparing a DBS PD group to a pre-DBS PD group and to a
control group of healthy participants. Secondarily, patients were
also assessed for depressive symptoms and cognitive functions.
Cognitive functions were assessed since deﬁcits in speciﬁc cog-
nitive domains, especially executive functions, could arise after
STN-DBS.
MATERIALS AND METHODS
PATIENTS
Three groups of subjects were involved in the case-control design:
27 consecutive PD patients bilaterally implanted for DBS of STN
(DBS group), 38 consecutive PD patients under dopaminergic
therapy (PRE-DBS group), and 27 healthy control subjects (C
group). All the participants gave their written informed consent to
the study after approval by the Ethics Committee of the University
of TurinMedical School. Conﬁdentiality and the right towithdraw
from the study were guaranteed to all the participants.
The patients of the DBS group successfully underwent DBS
of STN and were hospitalized at San Giovanni Battista Hospital
to adjust antiparkinsonian medication and electrical stimulator
parameters (1 year follow-up). The main inclusion criteria for
the surgical STN-DBS treatment were: diagnosis of idiopathic PD,
severe motor ﬂuctuations, drug-related dyskinesias, age under 70.
The main exclusion criteria were: marked atrophy or focal abnor-
malities on brain MRI, dementia, or relevant cognitive decline,
severe depression, and/or psychiatric disorders at the time of the
pre-surgical evaluation.
The patients of the pre-DBS group had not yet been surgically
treated, but satisﬁed the same inclusion criteria as the DBS group;
they were judged suitable for the surgical treatment and were on
the waiting list for STN-DBS surgery.
The two PD groups were matched for sex, age, years of educa-
tion, duration, and severity of illness (see Table 1). To evaluate
the severity of motor symptoms in order to match the two
PD groups, we used Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) -part III – motor scores (Members of the UPDRS devel-
opment committee et al., 1987): the DBS group was evaluated in
medication-off (MED-OFF)/stimulation-off (STIM-OFF) condi-
tion (after overnight withdrawal of antiparkinsonian medication
andwith stimulation switched off for at least 1 h), and the Pre-DBS
group in medication-off condition (MED-OFF; after overnight
withdrawal of antiparkinsonian medication).
After surgery, the DBS group obtained a signiﬁcant ameliora-
tion in UPDRS III scores; motor symptoms decreased by 66.2%
(pre-operative MED-OFF condition vs. post-operative STIM-
ON/MED-OFF conditions). Moreover, surgery allowed DBS PD
patients to reduce their drug intake: comparing pre- (mean:
1045.5 mg; SD: 423.2 mg) and post-surgery levodopa equiv-
alent daily dose (mean: 729.0 mg; SD: 305.3 mg), the DBS
group decreased their drug consumption by 30.3% [t(26) = 3.9;
p = 0.001].
The subjects of the C group were matched for age and years
of education to PD patients (DBS and pre-DBS groups). The
exclusion criteria for this group were: cognitive deﬁcits (MMSE
score ≤ 24), the presence of severe systemic or metabolic dis-
ease, intake of psychotropic medication, a history of psychiatric or
neurological illness, or substance abuse.
All the PD patients (DBS and pre-DBS groups) and subjects of
the C group underwent mood and alexithymia evaluation, with
the PD patients also undergoing a cognitive assessment. These
psychological and neuropsychological evaluations were made in
the MED-ON/STIM-ON condition for the DBS group, and in
MED-ON for the pre-DBS group.
COGNITIVE ASSESSMENT
The DBS and pre-DBS patients were given a standardized neu-
ropsychological test battery in order to assess reasoning, memory,
and attentional executive functions (Castelli et al., 2010). Visu-
ospatial reasoning was evaluated by means of the Raven Color
Matrices (PM 47; Raven, 1962); verbal, and spatial short-term
memory was assessed by means of the bisyllabic word repetition
test (BWR; Spinnler and Tognoni, 1987) and corsi’s block-tapping
test (Spinnler and Tognoni, 1987), respectively. The assessment
of verbal learning was achieved by means of the paired-associate
learning (PAL; Wechsler, 1945), a Wechsler Memory Scale subtest.
Frontal lobe executive functions, including the development of
abstract concepts and the shift of attention and motor sets, were
assessed by means of the Trail Making Test Part B (Reitan, 1958)
and the Nelson Modiﬁed Card Sorting Test (MCST; Nelson, 1976),
a modiﬁed version of the Wisconsin Card Sorting Test. In addi-
tion, patients were given phonemic (Benton, 1968) and category
(Spinnler and Tognoni, 1987) verbal ﬂuency tasks and a speciﬁc
battery for frontal functions, the Frontal Assessment Battery (FAB;
Dubois et al., 2000).
ALEXITHYMIA AND MOOD ASSESSMENT
Alexithymia was assessed by means of the Toronto Alexithymia
Scale (TAS-20; Bagby et al., 1994). TAS-20 is a validated self-report
20-item questionnaire with a ﬁve-point Likert response scale. It is
composed of three subscales that investigate three factors: difﬁ-
culty identifying feelings (F1; e.g., “I am often confused about
Frontiers in Psychology | Psychology for Clinical Settings October 2014 | Volume 5 | Article 1168 | 2
Castelli et al. Alexithymia in Parkinson’s disease
Table 1 | Clinical characteristics and neuropsychological data of the DBS, pre-DBS, and C groups.
DBS group Pre-DBS group CS group F (df) P
Clinical characteristics
Number of subjects 27 38 27 – –
Sex (male/female) 16/11 23/15 15/12 0.2(2)a –
Age 61.4(8.1) 59(7.4) 60.1(10.7) 0.6(2;89) 0.5
Years of education 9.5(3.6) 9(3.9) 11.2(3.3) 2.9(2;89) 0.06
DBS group Pre-DBS group – T (df) –
Duration of the dopaminergic treatment (years) 14.2(4.2) 12.7(4.8) – –1.5(63) –
Severity of the disease (UPDRS section III, off condition) 47.3(8.8) 44.3(6.3) – –1.6 (63) –
LEDD (levodopa equivalent daily dosage) 729.0(305.3) 980.1(353.1) – 3.0 (63) 0.004
Neuropsychological data
DBS group pre-DBS group – T (df) P
MMSE 27.9(1.5) 28.5(1.5) – 1.5(63) 0.1
Corsi’s Block-TappingTest 5(0.5) 5.5(0.9) – 2.6(63) 0.007
Raven Color Matrices 26.6(4.3) 27.7(5) – 0.9(63) 0.4
BisyllabicWord Repetition Test 4.1(08) 4.5(0.9) – 1.9(63) 0.01
Paired-Associate Learning 10.3(2.8) 11.1(2.7) – 1.2(63) 0.2
Trail mMakingTest Part B 261.9(165) 198.2(161.5) – –1.5(63) 0.1
Nelson Modiﬁed Card Sorting Test
Categories 5.6(0.7) 5.8(0.5) – 1(63) 0.3
Errors 6(5.1) 4.4(3.5) – –1.5(63) 0.1
Perseverations 2.6(2.2) 2.3(2.8) – –0.4(63) 0.7
Phonemic verbal ﬂuency 24.9(9.7) 33(10.1) – 3.3(63) 0.002
Category verbal ﬂuency 19(4.3) 20.9(4.5) – 1.7(63) 0.1
FAB 14.7(1.6) 16.1(1.5) – 3.5(63) 0.01
Mean (SD) and univariate ANOVAs (F)/t-tests (T) are shown. achi square.
what emotion I am feeling”); difﬁculty describing feelings (F2;
e.g., “I am often confused about what emotion I am feeling”),
difﬁculty focusing on inner affective experience (F3; e.g., “I pre-
fer talking to people about their daily activities rather than their
feelings”).
The total score ranges from 20 to 100 and allows subjects to be
categorized as “Non-alexithymic” (score from 20 to 50), “Border-
line” (score from 51 to 60), and “Alexithymic” (score ≥ 61; Castelli
et al., 2010).
Mood was evaluated by means of the Beck Depression Inven-
tory (BDI; Beck and Streer, 1987). The BDI, considered a reliable
instrument for the evaluation of depression severity in PD, is a
21-item self-rated questionnaire with a four-point Likert response
scale (0–3). The total score ranges from 0 (absence of depression)
to 63 (severe depression).
STATISTICAL ANALYSIS
Univariate ANOVAs for unpaired samples were run to compare
the test scores of the DBS, pre-DBS, and C groups; Bonferroni
analysis was used for post hoc two-by-two comparisons.
To compare the DBS and pre-DBS groups, we used a t-test
for independent samples. χ2 analysis was used to compare the
different prevalence of subjects among groups, i.e., number of
alexithymic subjects in the three groups. Finally, correlations
between variables were analyzed through Pearson correlation
analysis.
RESULTS
NEUROPSYCHOLOGICAL RESULTS: THE DBS GROUP VS PRE-DBS
GROUP
The neuropsychological test scores are shown in Table 1. The DBS
and pre-DBS groups evidenced statistically signiﬁcant differences
in spatial short-term memory (CPT; p = 0.007) and in some exec-
utive tests, i.e., the phonemic ﬂuency task (p = 0.002) and the FAB
(p = 0.01). In all three tests, the DBS patients performed worse
than the pre-DBS patients.
ALEXITHYMIA AND MOOD
The TAS and BDI scores of the three groups are given in Table 2.
Univariate ANOVAs showed signiﬁcant differences between the
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Table 2 | Comparison of alexithymia and mood (BDI) between the DBS, pre-DBS, and C groups.
DBS group Pre-DBS group CS group F (df) P Post hoc
Alexithymia
TAStot 54(10.1) 53.7(10.9) 46.1(11.2) 5(2;89) 0.009 DBS > CSbpre-DBS > CSb
F1 18.7(6) 18.4(6.6) 14.3(5.6) 4.5(2;89) 0.014 DBS > CSbpre-DBS > CSb
F2 13.6(4.2) 14(3.6) 12.4(4.6) 1.4(2;89) –
F3 21.7(3.9) 21.2(4.7) 19.4(4.9) 2(2;89) –
Mood
BDI 10.3(6.1) 14.1(8.1) 9.5(6.5) 4(2;89) 0.021 pre-DBS > CSb
Means (SD), univariate ANOVAs, and Bonferroni post hoc results are shown. bp < 0.05.
three groups in the TAS total score (p < 0.0001) and F1 scores
(p < 0.05), but not in the F2 and F3 subscales. With regard to
the TAS total score, as well as to the F1 subscale, post hoc analysis
underlined signiﬁcantly higher scores both in the DBS and pre-
DBS groups compared with the C group, while no difference was
found between the DBS and pre-DBS groups.
χ2 analysis conﬁrmed a signiﬁcantly different percentage of
alexithymic subjects in the three groups (χ2 = 9.54; p < 0.05).
Speciﬁcally, in the DBS and pre-DBS groups, 29.6% (8/27) and
31.6% (12/38), respectively, of the subjects resulted alexithymic,
compared with 14.8% (4/27) in the C group. As far as subclinical
disturbance is concerned (borderline score), 40.7% (11/27), 34.2%
(13/38), and 18.5% (5/27) of participants resulted borderline in
the DBS, pre-DBS, and CT groups, respectively.
Concerning mood, the three groups had signiﬁcantly different
BDI scores (p< 0.05). Post hoc analysis highlighted statistically sig-
niﬁcant differences between the pre-DBS and C groups (p< 0.05)
while, even if BDI scores of DBS patients are lower than C group
ones, this difference was not statistically signiﬁcant. These data
and results are given in Table 2.
CORRELATIONS BETWEEN VARIABLES IN THE PRE-DBS AND DBS
GROUP
No signiﬁcant correlation was found between TAS-20 total score
and severity of the disease (UPDRS -part III in the OFF condition)
both for the pre-DBS and DBS group.
Also no signiﬁcant correlation was found between TAS-20 total
and subscales scores and neuropsychological test scores, both for
the pre-DBS and DBS group.
As far as depression is concerned, correlation analysis showed
a signiﬁcant positive correlation between TAS-20 and BDI scores
in the pre-DBS group (r = 0.53; p = 0.001) while no signiﬁcant
correlation was found in the DBS group.
DISCUSSION
The question of the safety of STN-DBS and its effects on cogni-
tion and behavior is still open and controversial. To date, while
some studies have evaluated the effect of the surgical proce-
dure on mood, apathy, and anxiety, to our knowledge no study
has been conducted on alexithymia, despite the fact that this
affective dysregulation has a high prevalence – about 21% – in
the population of PD patients (not DBS treated) against 13–15
% in the general population (Costa et al., 2010; Assogna et al.,
2012).
Recent evidence has reported that PDpatients treatedwithDBS
of STNcouldbe at higher risk of suicidewith respect toPDpatients
not treated with DBS (Voon et al., 2008; Strutt et al., 2012), in so
much as suicide was deﬁned as “one of the most important poten-
tially preventable risks for mortality following STN-DBS for PD”
(Voon et al., 2008). This evidence highlights the need for further
studies on the neuropsychiatric effect of DBS surgery, especially
in the matter of depression and emotional dysregulation distur-
bances, since these factors can be predictive of suicidal ideation
and/or suicidal attempts (Voon et al., 2008). Indeed, completed
suicidehas been found tobe associatedwithpost-operative depres-
sion (Voon et al., 2008). In addition, suicidal ideation seems to
be more common in alexithymic subjects than non-alexithymic
subjects (Hintikka et al., 2004). One study carried out on the
general population has suggested that when depression presents
alexithymic features, the affected person has an additive impact on
the risk of suicidal ideation (Hintikka et al., 2004).
The principal aim of this study was to investigate whether STN-
DBS would affect alexithymic features, by means of a comparison
of a matched control group of PD patients under pharmacologi-
cal treatment only and a matched group of healthy subjects. Our
results suggest that STN-DBS does not affect alexithymia. The
TAS score results (total score and three factors) highlighted no sig-
niﬁcant differences between surgically and non-surgically treated
PD patients. In actual fact, we found similar percentages of alex-
ithymia in the DBS and pre-DBS groups: 29.6% (8/27) and 31.6
(12/38), respectively.
This said, the DBS and pre-DBS groups both showed twice
the prevalence of alexithymia compared with the C group: 14.8%
(4/27). As far as the three features of alexithymia were concerned,
the results evidenced a signiﬁcant difference only in the factor con-
cerning “difﬁculty in distinguishing physiological from emotional
state” (F1). In this case, too, as well as for the TAS total score, the
DBS and pre-DBS groups both evidenced a statistically signiﬁcant
higher score than the subjects of the control group.
Irrespective of the effect of DBS, our results conﬁrmed the high
prevalence of alexithymia in medically treated PD patients (Costa
et al., 2010; Assogna et al., 2012). Our prevalence was even higher
than that of Costa et al. (2010) and Assogna et al. (2012) 22 and
21%, respectively, against 31.6% in our sample.
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This difference could probably result from differences in
patients’ characteristics, such as severity of disease and dopamin-
ergic treatment dosage, both higher in our sample (see Table 1)
than in these other studies sample (Costa et al., 2010;Assogna et al.,
2012). As far as the TAS subscales are concerned, we found a signif-
icant difference in the “difﬁculty identifying feelings” (F1) factor
between the pre-DBS and C groups. This result agrees with the
evidence of Assogna et al. (2012), while another study has shown
a difference only in the F2 subscale “difﬁculty describing feelings”
(Costa et al., 2010).
Neuropsychological tests results showed a signiﬁcantly worse
performance of DBS patients (vs. pre-DBS) on some atten-
tion/executive tests, especially on the phonemic ﬂuency task. This
evidence is in line with previous studies focusing on cognitive
STN-DBS outcome (Parsons et al., 2006; Witt et al., 2008; Castelli
et al., 2010). In addition, while conﬁrming that DBS-STN did not
lead to general cognitive deterioration, neuropsychological results
highlighted that speciﬁc cognitive domains, such as attention and
executive functions, can by negatively affected by this surgical
procedure.
In regards to this aspect, it is important to note that alex-
ithymic symptoms can be related to neuroanatomical dysfunction,
i.e., right hemisphere or frontal lobe damage, especially anterior
cingulate cortex dysfunctioning (Berthoz et al., 2002; Costa et al.,
2007; Assogna et al., 2012). Even if this issue is still controversial – a
recent study suggest that“the personality trait of alexithymiamight
be associated with fewer morphological abnormalities than previ-
ously assumed” (Heinzel et al., 2012) – it is important to remark
that alexithymia can be related and, possibly consequent, to the
other symptoms usually present in PD patients, i.e., depression,
apathy, and cognitive impairment, all of which may have overlap
with alexithymia. So, even if our correlation results did not show
a relation between cognitive tests and alexithymia results, we can
not exclude that alexithymic features can be related or consequent
to cognitive deﬁcits. Further studies on these aspects are needed.
As far as depressive symptoms are concerned, our results evi-
denced that the pre-DBS group was more depressed than the
C group, while no difference emerged between the DBS and C
groups. This evidence seems to conﬁrm the results of previous
studies showing a positive effect of STN-DBS on depressive symp-
toms (Castelli et al., 2006), even though, as previously stated,
this issue is still debated and other studies have pointed out a
post-surgery increase in depressive symptoms (Strutt et al., 2012).
To date, there is no univocal explanation for depressive symp-
toms amelioration after STN-DBS.The improvement indepressive
symptoms could be a consequence of motor symptoms reduction
as well as it could reﬂect the intrinsic role of the STN in non-motor
circuits and related symptoms (Witt et al., 2012).
The results for alexithymia and depression suggest that circuits
beneath alexithymia and depression are not totally overlapped
(Poletti et al., 2011). Although many studies have pointed out a
strict correlation between depressive symptoms and alexithymic
traits in both the general and clinical population (Hintikka et al.,
2004; Costa et al., 2010), a recent study suggests that alexithymia is
a depressive-independent phenomenon in PD patients (Assogna
et al., 2012). Our results seem to indirectly conﬁrm this last
hypothesis: while depressive symptoms are lower after surgery
(comparable to C group level), this is not the case with alexithymic
features. Moreover we found a signiﬁcant correlation between
alexithymia and depression only in the pre-DBS group but not
in the DBS group. On this basis, depression and alexithymia can
be considered two distinct but partially overlapped clinical phe-
nomena. Further, it can be supposed that STN-DBS intervention
could inﬂuence some circuits implicated in depression but not in
alexithymia.
In conclusion, the ﬁndings of this study suggest that STN-DBS
intervention seems to have some effect on depressive symptoms,
but not on alexithymic traits. Actually, on the one hand depres-
sive symptoms in DBS patients are comparable to those in the C
group, while pre-DBS patients were found to be more depressed
than controls subjects. On the other hand alexithymia was present
in the same percentage in the two groups of patients (DBS and
pre-DBS). Furthermore, the comparison with a control group of
healthy matched subjects allows us to conﬁrm the high prevalence
of alexithymia in PD patients. This evidence points out once again
the importance of taking into account psychological aspects aswell
as cognitive outcome and the relation between these two domains
in order to conduct a multidisciplinary assessment and treatment
for patients undergoing STN-DBS surgery.
LIMITATION
Provided that, to our knowledge, this is the ﬁrst study investigating
alexithymia in STN-DBS treated PD patients and that we used a
case-control design with both a matched control group of PD
patients not treated with DBS and a matched group of healthy
participants, further studies using a prospective design (pre- vs.
post-operative evaluation) are needed in order to conﬁrm our
ﬁndings and to draw more deﬁnitive claims.
In addition we could not investigate the possible role of antide-
pressant medications on psychological variables due to the great
number of incomplete or missing psychopharmacological data.
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